Neurotensin receptor 1 overexpression in inflammatory bowel diseases and colitis-associated neoplasia

Table 1 Neurotensin receptor 1 expression in 18 cases of inflammatory bowel diseases with colectomy n (%)

Histology	Case				P value
	Negative	1+	2+	3+
Normal	12 (100.00)	0 (0.00)	0 (0.00)	0 (0.00)
Colitis	1 (3.23)	20 (64.52)	10 (32.36)	0 (0.00)
Active	0 (0.00)	12 (75.00)	4 (25.00)	0 (0.00)
Inactive	1 (6.67)	8 (53.33)	6 (40.00)	0 (0.00)	0.3381
LGD	0 (0.00)	3 (18.75)	11 (68.75)	2 (12.50)	0.0072
DALM	0 (0.00)	3 (25.00)	7 (58.33)	2 (16.67)
ALDP	0 (0.00)	0 (0.00)	4 (100.00)	0 (0.00)	0.2981
HGD	0 (0.00)	1 (9.09)	4 (36.36)	6 (54.55)	0.0633
CACRC	0 (0.00)	1 (7.69)	4 (30.77)	8 (61.54)	0.0223

¹Within two subgroups (active vs inactive);

²As compared with colitis;

³As compared with low-grade dysplasia (LGD). HGD: High-grade dysplasia; DALM: Dysplasia-associated lesions or masses; ALDP: Adenoma-like dysplastic polyps; CACRC: Colitis-associated colorectal carcinoma.

Table 2 Neurotensin receptor 1 expression n (%)

	Negative	1+	2+	3+
SAP	0	4 (23.53)	8 (47.06)	5 (29.41)
DALM	0	7 (41.42)	7 (41.42)	3 (17.65)
SCRC	0	0	1 (8.33)	11 (91.67)
CACRC	0	1 (7.69)	4 (30.77)	8 (61.54)

Comparison between colitis-associated dysplasia/carcinoma and sporadic dysplasia/carcinoma. Sporadic colorectal adenomatous polyp (SCRC) vs colitis-associated colorectal carcinoma (CACRC), P = 0.198; Dysplasia-associated lesions or masses (DALMs) vs CACRC, P = 0.028; DALMs vs sporadic colorectal carcinomas (SAPs), P = 0.50.